ASTONEA LABS LIMITED

BSE: ASTONEALAB544409ISIN INE0TG901011

Healthcare
Pharmaceuticals

Share price

₹335.00+5.00 (+1.52%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹369.00
52W low: ₹118.00
Off 52W high: -9.21%
1M return: 0.00%
3M return: +24.07%
6M return: +99.52%
1Y return: +114.74%
20D avg volume: 4,550
50 DMA: ₹298.62
200 DMA: ₹206.12

Key ratios Consolidated

Market cap: ₹352.12 Cr
Current price: ₹335.00
52W high / low: ₹369.00 / ₹118.00
Face value: ₹10.00
P/E: —
P/B: —
EPS (TTM): —
Book value / share: —
ROE: —
ROCE: 11.30%
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: 2.72
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 111.7 days

Financials

Metric	FY26	FY25
Income statement
	147.58	—
	0.52	—
	148.10	—
	142.48	—
	102.79	—
	0.00	—
	7.63	—
	3.26	—
	28.22	—
	5.62	—
	0.00	—
	5.62	—
	1.11	—
	4.51	—
	4.49	—
Key metrics
	8.88	—
	6.00%	—
	3.10%	—
	11.30%	—
	-27.63	—
	-3.03	—
	111.7	—
Balance sheet
	146.26	—
	98.09	—
	0.18	—
	52.03	—
	33.61	—
	31.04	—
	40.47	—
	67.89	—
Cash flow
	-13.65	—
	-19.90	—
	33.64	—
	13.98	—

Metric	FY26	FY25	FY24
Income statement
	147.58	97.52	—
	0.52	0.19	—
	148.10	97.71	—
	142.48	90.64	—
	102.79	57.06	—
	0.00	9.83	—
	7.63	6.70	—
	3.26	3.66	—
	4.99	4.58	—
	28.22	9.03	—
	5.62	7.07	—
	5.62	7.07	—
	1.11	1.72	—
	4.51	5.35	—
	4.49	6.94	—
Key metrics
	13.87	15.31	—
	9.40%	15.70%	—
	3.10%	5.50%	—
	11.30%	26.50%	—
	51.30%	—	—
	-15.70%	—	—
	-27.63	-1.54	—
	-3.03	1.73	—
	111.7	153.4	—
Balance sheet
	146.26	103.38	—
	98.09	70.85	—
	0.18	0.09	—
	52.03	37.86	—
	33.61	29.35	—
	—	0.00	—
	31.04	24.80	—
	40.47	26.24	—
	67.89	62.94	—
Cash flow
	-13.65	9.25	—
	-19.90	-11.14	—
	33.64	1.62	—
	13.98	10.79	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 72.43%

Holder	Type	Holding	Previous	Change
ASHISH GULATI	Promoter	70.94%	—	—
GURVINDER SINGH BHULLAR	Public	3.29%	—	—
DEEPAK KUMAR AGARWAL	Public	2.15%	—	—
MRIDUL AGARWAL	Public	1.46%	—	—
HARSH GULATI	Promoter Group	0.72%	—	—
USHA GULATI	Promoter Group	0.72%	—	—
NEHA DUTTA GULATI	Promoter Group	0.05%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
ASTONEA LABS LIMITED	352	335.00	—	11.30%	—	—	+114.74%

Filings & corporate actions

Recent announcements

Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated ....30 Oct 2026 · Board Meeting / Board Meeting
Please find enclosed herewith an Intimation regarding change in the Corporate Identification Number (CIN) of the Company consequent upon alteration of the Object Clause of the Memorandum ....9 Oct 2026 · Company Update / General
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Incorporation of Proposed Subsidiary- Longevity Science Private Limited8 Oct 2026 · Company Update / General
Please find enclosed herewith the Certificate under Reg. 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, pertaining to the quarter ended 30.09.2026.8 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for Closure of Trading Window.25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed herewith re-submission of financial results for the half year and year ended 31.03.2025.22 Sep 2026 · Result / Financial Results
Please find enclosed herewith resubmission of financial results for the financial year ended 31.03.2025, as the same was submitted in XBRL Version and as a part of outcome of the Board ....19 Sep 2026 · Result / Financial Results
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashish Gulati18 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Please find enclosed herewith disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulation, 2015 as received from Mr. Ashish Gulati, Promoter of the Company.17 Sep 2026 · Company Update / General
Please find enclosed herewith disclosure as per Regulation 29(1) of SEBI (Substantial Acquisition of shares & Takeovers) Regulation, 2011 as received from Mr. Ashish Gulati, Promoter of the Company.17 Sep 2026 · Company Update / General
Intimation under Regulation 30-Appointment of Internal Auditor9 Sep 2026 · Company Update / General
Outcome of the Board Meeting held on 9th September, 2026.9 Sep 2026 · Others / Outcome without intimation
Approval of Alteration in Object Clause of the Memorandum of Association ("MOA") of the Company21 Aug 2026 · Company Update / Amendments to Memorandum & Articles of Association
Re-appointment of Ms. Pooja Singh as Director of the Company21 Aug 2026 · Company Update / General
Scrutinizer''s Reports and Voting Results of the 9th Annual General Meeting ("AGM") of the Company held on 21st August, 202621 Aug 2026 · AGM/EGM / AGM
Proceedings of 9th Annual General Meeting ("AGM") of the Company for the financial year 2025-26 held on 21st August, 202621 Aug 2026 · AGM/EGM / AGM
Intimation regarding Newspaper Publication of Notice of 9th Annual General Meeting ("AGM") of the Company.25 Jul 2026 · Company Update / Newspaper Publication
Annual Report of the Company for the Financial year 2025-26.24 Jul 2026 · Others / Reg. 34 (1) Annual Report
Please find enclosed herewith an attached Notice of 9th Annual General Meeting ("AGM") of the Company for the Financial Year 2025-26 scheduled to be held on Friday, 21st August, 2026.24 Jul 2026 · AGM/EGM / AGM
Intimation under Regulation 30- Revision in Re-appointment of Tax Auditor under Income Tax Act, 202524 Jul 2026 · Company Update / General
Audited Consolidated Financial Results for the Half year and year ended 31.03.202624 Jul 2026 · Result / Financial Results
Outcome of the Board Meeting held on 24th July, 202624 Jul 2026 · Board Meeting / Outcome of Board Meeting
Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 ,inter alia, to consider and approve Audited Consolidated Financial ....18 Jul 2026 · Board Meeting / Board Meeting
Intimation under Regulation 30 of SEBI(LODR)Regulations, 2015 - Execution and Registration of Sale Deed for Sale of Immovable Properties located in Gurugram, Haryana.17 Jul 2026 · Company Update / General
Intimation under Regulation 30 regarding successful completion of Regulatory Inspection of Manufacturing Facility by Supreme Board of Drugs and Medical Appliances (SBDMA), Ministry of Health ....14 Jul 2026 · Company Update / General
Please find enclosed herewith the Certificate under Reg. 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, pertaining to the quarter ended 30.06.2026.13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed the Revised Financial Results along with the additional documents sought by BSE through its email dated 19th June 202620 Jun 2026 · Result / Financial Results
Submission of Half-Yearly Disclosure on Related Party Transactions for the period ended 31.03.202630 May 2026 · Company Update / General
Statement of Deviation & Variation for the half year ended 31.03.202630 May 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Intimation under Regulation 30- Re-appointment of Tax Auditor30 May 2026 · Company Update / General
Intimation under Regulation 30- Re-appointment of Cost Auditor30 May 2026 · Company Update / General
Intimation under Regulation 30- Re-appointment of Secretarial Auditor30 May 2026 · Company Update / General
Audited Standalone Financial Results for the half year and year ended 31.03.202630 May 2026 · Result / Financial Results
Outcome of the Board Meeting held on 30th May, 202630 May 2026 · Board Meeting / Outcome of Board Meeting
Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Audited Financial Results (Standalone ....25 May 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....29 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Intimation under Regulation 30 of SEBI LODR (Regulations), 2015 regarding Fire Incident at premises of Company''s Manufacturing Facility27 Apr 2026 · Company Update / General
Please find enclosed herewith a statement on redressal of Investor Grievances for the quarter ended 31.03.202623 Apr 2026 · Company Update / General
Please find enclosed herewith the Certificate under Reg. 74 (5) of SEBI (Depositories & Participants) Regulations, 2018, pertaining to the quarter ended 31.03.2026.9 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Acquisition of Equity Stake in Damaira Pharmaceuticals Private Limited31 Mar 2026 · Company Update / Acquisition

Board meetings

14 Nov 2026 Board Meeting - Financial Results
24 Jul 2026 Board Meeting - Financial Results